FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  COMMISSIONG JOHN WESLEY
2. Date of Event Requiring Statement (Month/Day/Year)
08/02/2013
3. Issuer Name and Ticker or Trading Symbol
Amarantus Bioscience Holdings, Inc. [AMBS]
(Last)
(First)
(Middle)
C/O 655 MONTGOMERY STREET, STE. 900
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SAN FRANCISCO, CA 94111
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 19,994,190
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Common Stock 04/10/2011 04/10/2021 Common Stock 131,557 $ 0.0237 D  
Series C Convertible Preferred Stock 04/03/2013   (1) Common Stock 200,000 $ (2) D  
Warrants to Purchase Common Stock 10/02/2014 10/02/2016 Common Stock 138,889 $ 0.06 D  
Options to Purchase Common Stock 01/12/2015 01/12/2025 Common Stock 3,500,000 (3) $ 0.08 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
COMMISSIONG JOHN WESLEY
C/O 655 MONTGOMERY STREET, STE. 900
SAN FRANCISCO, CA 94111
  X     Chief Scientific Officer  

Signatures

/s/ John Commissiong 01/15/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Not applicable.
(2) Each share of Series C Convertible Preferred Stock is convertible into 1 shares of the Issuer's common stock.
(3) Granted to Reporting Person by the Issuer pursuant to the Reporting Person's employment agreement with the Issuer, and shall vest in equal monthly installments beginning on the date of grant for a period of 36 months until it is entirely vested, subject to continued employment with the Issuer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.